Fact CheckerSign in

NCT07205081CompletedPhase 1

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis

Source: ClinicalTrials.gov · Last updated 11 Sept 2026

Brief summary (registry, in English)

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
48 (actual)
First submitted
24 Sept 2025
Start date
22 Oct 2025
Primary completion date
13 Aug 2026
Lead sponsor
Attovia Therapeutics Inc
NCT number
NCT07205081

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 48
  • From 22 Oct 2025 to the primary completion date, 13 Aug 2026
  • 17 sites in 3 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria:
  • Any sex or gender who is 18 to 65 years old, inclusive, at Screening.
  • Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2
  • Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs
  • Negative pregnancy test for participants of child-bearing potential.
    • Part 3 (Participants with Atopic Dermatitis) Key Inclusion Criteria:
  • Any sex or gender who is 18 to 65 years old
  • Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2
  • Clinically confirmed diagnosis of active AD
  • History of inadequate response to treatment with topical medications
  • Baseline weekly mean of daily PP-NRS ≥ 4 at Day 1.
  • EASI score of ≥ 16 at Screening and Day 1
  • vIGA-AD score of ≥ 3 at Screening and Day 1
  • ≥10% of body surface area (BSA) affected by AD at Screening and Day 1
  • Use of topical bland emollient (moisturizer) at least once daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study
  • Negative pregnancy test for participants of childbearing potential
    • Parts 1 \& 2 (Healthy Volunteers) Key Exclusion Criteria
  • Any clinically significant underlying illness
  • History of malignancy within 5 years of Screening
  • History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
  • History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week
  • History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
  • Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV
  • Active or latent tuberculosis infection
  • Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day
  • History of drug or alcohol abuse
  • Laboratory values outside of the normal range
    • Part 3 (Participants with Atopic Dermatitis) Key Exclusion Criteria:
  • Any clinically significant underlying illness
  • Presence of skin comorbidities that may interfere with study assessments
  • Has taken prescription medication for the treatment of AD or other prohibited medication within the restricted time limits (defined in the protocol)
  • Has applied topical corticosteroids within 2 weeks prior to dosing.
  • History of malignancy within 5 years of Screening
  • History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
  • History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week
  • History of recurrent eczema herpeticum
  • History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months
  • History of major depression
  • History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
  • Participant has experienced significant flare(s) in AD in the 2 weeks prior to Screening or during the Screening period
  • EASI score for the participant has more than doubled between Screening and Day 1
  • Active HBV or HCV or is positive for HIV
  • Participant is smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day
  • Participant has an ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening
  • History of drug or alcohol abuse
  • Laboratory values outside of the normal range

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (17)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Altasciences
Coordinator of this site? Confirm its status
MontrealCanadaUnknown status
-
Coordinator of this site? Confirm its status
PeterboroughCanadaUnknown status
-
Coordinator of this site? Confirm its status
AucklandNew ZealandUnknown status
-
Coordinator of this site? Confirm its status
AucklandNew ZealandUnknown status
-
Coordinator of this site? Confirm its status
ChristchurchNew ZealandUnknown status
-
Coordinator of this site? Confirm its status
HamiltonNew ZealandUnknown status
-
Coordinator of this site? Confirm its status
NelsonNew ZealandUnknown status
-
Coordinator of this site? Confirm its status
WellingtonNew ZealandUnknown status
-
Coordinator of this site? Confirm its status
Coral GablesUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
EncinitasUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
Fountain ValleyUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
Huntington BeachUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
IndianapolisUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
RocklinUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
Saint JosephUnited StatesUnknown status
-
Coordinator of this site? Confirm its status
SweetwaterUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.